170 related articles for article (PubMed ID: 8650193)
1. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.
Chen YT; Stockert E; Jungbluth A; Tsang S; Coplan KA; Scanlan MJ; Old LJ
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5915-9. PubMed ID: 8650193
[TBL] [Abstract][Full Text] [Related]
2. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
4. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
5. Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis.
Jungbluth AA; Iversen K; Coplan K; Williamson B; Chen YT; Stockert E; Old LJ; Busam KJ
Virchows Arch; 1999 May; 434(5):429-35. PubMed ID: 10389626
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
[TBL] [Abstract][Full Text] [Related]
7. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
Jäger E; Ringhoffer M; Altmannsberger M; Arand M; Karbach J; Jäger D; Oesch F; Knuth A
Int J Cancer; 1997 Apr; 71(2):142-7. PubMed ID: 9139833
[TBL] [Abstract][Full Text] [Related]
8. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A.
Giudice C; Ceciliani F; Rondena M; Stefanello D; Grieco V
J Vet Diagn Invest; 2010 May; 22(3):389-94. PubMed ID: 20453212
[TBL] [Abstract][Full Text] [Related]
10. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
11. Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven canine melanoma cells lines and twenty-nine retrospective cases of canine melanoma.
Koenig A; Wojcieszyn J; Weeks BR; Modiano JF
Vet Pathol; 2001 Jul; 38(4):427-35. PubMed ID: 11467477
[TBL] [Abstract][Full Text] [Related]
12. Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions.
Butterfield LH; Stoll TC; Lau R; Economou JS
Gene; 1997 Jun; 191(2):129-34. PubMed ID: 9218710
[TBL] [Abstract][Full Text] [Related]
13. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.
Kurnick JT; Ramirez-Montagut T; Boyle LA; Andrews DM; Pandolfi F; Durda PJ; Butera D; Dunn IS; Benson EM; Gobin SJ; van den Elsen PJ
J Immunol; 2001 Aug; 167(3):1204-11. PubMed ID: 11466335
[TBL] [Abstract][Full Text] [Related]
14. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.
Chen YT; Stockert E; Chen Y; Garin-Chesa P; Rettig WJ; van der Bruggen P; Boon T; Old LJ
Proc Natl Acad Sci U S A; 1994 Feb; 91(3):1004-8. PubMed ID: 8302824
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a screening system for chemicals that upregulate a melanoma antigen, Melan-A/MART-1.
Song HZ; Kono M; Tomita Y
Tohoku J Exp Med; 2009 Mar; 217(3):231-7. PubMed ID: 19282659
[TBL] [Abstract][Full Text] [Related]
16. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
17. Use of immunocytochemical techniques in canine melanoma.
Höinghaus R; Mischke R; Hewicker-Trautwein M
J Vet Med A Physiol Pathol Clin Med; 2002 May; 49(4):198-202. PubMed ID: 12069262
[TBL] [Abstract][Full Text] [Related]
18. Melan-A, a new melanocytic differentiation marker.
Busam KJ; Jungbluth AA
Adv Anat Pathol; 1999 Jan; 6(1):12-8. PubMed ID: 10197235
[TBL] [Abstract][Full Text] [Related]
19. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Kawakami Y; Battles JK; Kobayashi T; Ennis W; Wang X; Tupesis JP; Marincola FM; Robbins PF; Hearing VJ; Gonda MA; Rosenberg SA
J Immunol Methods; 1997 Mar; 202(1):13-25. PubMed ID: 9075767
[TBL] [Abstract][Full Text] [Related]
20. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.
Nicotra MR; Nisticò P; Mangoni A; Di Filippo F; Marincola FM; Natali PG
J Immunother; 1997 Nov; 20(6):466-9. PubMed ID: 9409452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
